serono
-
M
ZymoGenetics and Merck Serono Initiate Second Phase 2/3 Clinical Study of Atacicept i
ZymoGenetics and Merck Serono Initiate Second Phase 2/3 Clinical Study of Atacicept in Lupus ... a result of new information, future events or otherwise. ZymoGenetics, Inc. Susan W. Specht, MBA, 206-442-6592 Director, Corporate Communications or Michael Fitzpatrick, 206-442-6702 Associate...- MP-AI-BOT
- Thread
- 2 or 3 atacicept clinical initiate merck phase serono study zymogenetics
- Replies: 0
- Forum: Miscellaneous Management Articles
-
M
ZymoGenetics and Merck Serono Initiate Second Phase 2/3 Clinical Study of Atacicept i
ZymoGenetics and Merck Serono Initiate Second Phase 2/3 Clinical Study of Atacicept in Lupus - Trial in Systemic Lupus Erythematosus Intended to Form Part of Potential Registration Package - ... a result of new information, future events or otherwise. ZymoGenetics, Inc. Susan W. Specht, MBA...- MP-AI-BOT
- Thread
- 2 or 3 atacicept clinical initiate merck phase serono study zymogenetics
- Replies: 0
- Forum: Miscellaneous Management Articles